520 related articles for article (PubMed ID: 27038842)
1. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma.
Workel HH; Komdeur FL; Wouters MC; Plat A; Klip HG; Eggink FA; Wisman GB; Arts HJ; Oonk MH; Mourits MJ; Yigit R; Versluis M; Duiker EW; Hollema H; de Bruyn M; Nijman HW
Eur J Cancer; 2016 Jun; 60():1-11. PubMed ID: 27038842
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.
Webb JR; Milne K; Watson P; Deleeuw RJ; Nelson BH
Clin Cancer Res; 2014 Jan; 20(2):434-44. PubMed ID: 24190978
[TBL] [Abstract][Full Text] [Related]
3. PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.
Webb JR; Milne K; Nelson BH
Cancer Immunol Res; 2015 Aug; 3(8):926-35. PubMed ID: 25957117
[TBL] [Abstract][Full Text] [Related]
4. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.
Komdeur FL; Wouters MC; Workel HH; Tijans AM; Terwindt AL; Brunekreeft KL; Plat A; Klip HG; Eggink FA; Leffers N; Helfrich W; Samplonius DF; Bremer E; Wisman GB; Daemen T; Duiker EW; Hollema H; Nijman HW; de Bruyn M
Oncotarget; 2016 Nov; 7(46):75130-75144. PubMed ID: 27650547
[TBL] [Abstract][Full Text] [Related]
5. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.
Webb JR; Wick DA; Nielsen JS; Tran E; Milne K; McMurtrie E; Nelson BH
Gynecol Oncol; 2010 Sep; 118(3):228-36. PubMed ID: 20541243
[TBL] [Abstract][Full Text] [Related]
6. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J; Kim S; Kim MY; Go H; Jeon YK; Chung DH
Oncotarget; 2017 Feb; 8(8):13762-13769. PubMed ID: 28099920
[TBL] [Abstract][Full Text] [Related]
8. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
9. Effector T lymphocyte subsets in human pancreatic cancer: detection of CD8+CD18+ cells and CD8+CD103+ cells by multi-epitope imaging.
Ademmer K; Ebert M; Müller-Ostermeyer F; Friess H; Büchler MW; Schubert W; Malfertheiner P
Clin Exp Immunol; 1998 Apr; 112(1):21-6. PubMed ID: 9566785
[TBL] [Abstract][Full Text] [Related]
10. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
11. The Emerging Role of CD8
Corgnac S; Boutet M; Kfoury M; Naltet C; Mami-Chouaib F
Front Immunol; 2018; 9():1904. PubMed ID: 30158938
[TBL] [Abstract][Full Text] [Related]
12. ITGAE Defines CD8+ Tumor-Infiltrating Lymphocytes Predicting a better Prognostic Survival in Colorectal Cancer.
Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
EBioMedicine; 2018 Sep; 35():178-188. PubMed ID: 30100393
[TBL] [Abstract][Full Text] [Related]
13. CD103 and Intratumoral Immune Response in Breast Cancer.
Wang ZQ; Milne K; Derocher H; Webb JR; Nelson BH; Watson PH
Clin Cancer Res; 2016 Dec; 22(24):6290-6297. PubMed ID: 27267849
[TBL] [Abstract][Full Text] [Related]
14. CD8+CD103+ tissue-resident memory T cells convey reduced protective immunity in cutaneous squamous cell carcinoma.
Lai C; Coltart G; Shapanis A; Healy C; Alabdulkareem A; Selvendran S; Theaker J; Sommerlad M; Rose-Zerilli M; Al-Shamkhani A; Healy E
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479027
[TBL] [Abstract][Full Text] [Related]
15. CD103+ intraepithelial lymphocytes--a unique population in microsatellite unstable sporadic colorectal cancer.
Quinn E; Hawkins N; Yip YL; Suter C; Ward R
Eur J Cancer; 2003 Mar; 39(4):469-75. PubMed ID: 12751377
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral CD103-positive tumour-infiltrating lymphocytes are associated with favourable prognosis in patients with triple-negative breast cancer.
Park MH; Kwon SY; Choi JE; Gong G; Bae YK
Histopathology; 2020 Oct; 77(4):560-569. PubMed ID: 32333690
[TBL] [Abstract][Full Text] [Related]
17. Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas.
Cresswell J; Robertson H; Neal DE; Griffiths TR; Kirby JA
Clin Exp Immunol; 2001 Dec; 126(3):397-402. PubMed ID: 11737053
[TBL] [Abstract][Full Text] [Related]
18. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
[TBL] [Abstract][Full Text] [Related]
19. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
20. Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.
Mann JE; Smith JD; Birkeland AC; Bellile E; Swiecicki P; Mierzwa M; Chinn SB; Shuman AG; Malloy KM; Casper KA; McLean SA; Moyer JS; Wolf GT; Bradford CR; Prince ME; Carey TE; McHugh JB; Spector ME; Brenner JC
Cancer Immunol Immunother; 2019 Feb; 68(2):213-220. PubMed ID: 30361882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
